DrugsIn 2023, 2 novel pharmaceutical agents for small animals were released on the German market: the structural but non-functional analog of the inhibitory neurotransmitter gamma-aminobutyric acid pregabalin with an anxiolytic active component and the dopamine agonist ropinirole in form of eye drops ...
DrugsIn 2023, no new active pharmaceutical ingredients were released on the German market for horses and food-producing animals. Two established veterinary active pharmaceutical ingredients became available for additional species: The phosphorus compound butafosfan was also approved for horses, dogs, and...
doi:10.1080/13543784.2024.2377322Na Hyun KimMehdi HamadaniSameem AbedinExpert Opinion on Investigational Drugs
This review provides an overview of the synthesis and clinical applications of NCEs approved by the FDA in 2024. The increasing importance of clinical applications has also been discussed. This review aims to provide valuable insights for the design of future drugs, particularly in the context of ...
Investigational New Drugs is a forum for rapid dissemination of information on new anticancer agents. The journal publishes original articles dealing with ...
New multi-target drugs in 2023–2024– evaluation Newly introduced drugs are subject to at least two systems of evaluation after their introduction in Germany. The first evaluation system is described in thePharmazeutische Zeitung, a weekly appearing journal for pharmacists, in which the degree of ...
Orphan drugsThe US Food and Drug Administration approved 50 new drugs and nine new cellular and gene therapy products in 2024, i.e., a total of 59 new medical therapies. The latter group represented three treatments each for oncology and hematology/immunotherapy, and one each for neurology, ...
WelcometoFDA’sCenterforDrugEvaluationandResearch’s(CDER)14thannual report,AdvancingHealthThroughInnovation:NewDrugTherapyApprovals.The2024NewDrugTherapyApprovalsreportisdesignedtoshowcaseCDER’sroleinbringingsafeandeffectivedrugstomarketforpatientsandconsumers. ThisreportdescribesCDER’s2024notabledrugapprovals,which...
New drugs to prevent oxaliplatin-induced peripheral neuropathy: A double-blind, randomized study.doi:10.1200/JCO.2024.42.16_suppl.35686313568#Background:Postoperative adjuvant chemotherapy for colorectal cancer reduces postoperative recurrence; however, it often causes undesirable adverse events. Oxaliplatin...
Purpose of reviewThis review addresses the emerging role of antibody-drug conjugates (ADCs) in the treatment of ovarian cancer, a field marked by a high need for more effective and targeted therapies. Given the recent advancements in ADC technology and the ongoing challenges in treating ovarian ...